Lazzarato David Angelo sold $21K of CGC

Lazzarato David Angelo sold 22,380 shares of Canopy Growth Corp (CGC) at $0.93 on 2026-09-28.

Original reporting
SEC EDGAR · Lazzarato David Angelo
Published Sep 30, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CGC
Neutral
medium confidence
Mentioned
$CGC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGCNeutralLow
01

Why it matters

The disclosed sale is small and unlikely to move the stock significantly, but it provides a data point for monitoring insider sentiment.

02

Market read

A routine insider sale with limited market impact; useful for tracking insider behavior but not a catalyst for immediate trading.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 3/10Novelty 3/10Timing: post‑filing today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$CGCNeutralMedium confidence
Context

Director Lazzarato sold 22,380 shares for $20,741, reducing his stake to 189,479 shares.

Expected impact

likely slight downward pressure as investors digest the director's sale

Evidence & confidence

The transaction size is small relative to market cap and typical daily volume, so impact is limited.

Market effects

Minimal; cannabis sector not materially affected by a single director's modest sale.

None

None

Counterpoint

The sale could be routine portfolio rebalancing and not indicative of company fundamentals.

Key entities

  • Canopy Growth Corp

    Cannabis producer listed on NYSE under ticker CGC.

  • Lazzarato David Angelo

    Director of Canopy Growth Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CGCMed

Canopy Growth (CGC) Q2 2027 Earnings Call Transcript

Canopy Growth (CGC) reported Q2 2027 revenue of $81.4M, up 22% YoY, driven by 30% cannabis segment growth. Medical cannabis and international markets showed momentum, while Storz & Bickel revenue fell 44% YoY to $50.1M. The company expects improved yields and EU GMP certifications to boost growth and margins. Adjusted EBITDA loss narrowed to $2.9M, with a target of profitability in H2 2027.

$CGCMedAI 8/10

Canopy Growth Corporation Q2 2027 Earnings Call Summary

Canopy Growth reported Q2 2027 results, highlighting a 141% YoY increase in international cannabis revenue and a 44% decline in Storz & Bickel revenue due to economic uncertainty. The company aims for positive adjusted EBITDA in H2 2027, with cultivation improvements expected to boost flower production by 25-30% in early 2028. Canopy also secured EU GMP certification, enabling expansion into European markets beyond dry flower.

$CGCMed

Canopy Growth Q2 Earnings Call Highlights

Canopy Growth reported Q2 revenue growth in Canada and plans to build a dedicated sales force. Storz & Bickel revenue declined 4% but expects a strong Q3. Cultivation improvements aim for 25-30% yield increase. Adjusted gross margin fell to 31% from 33% due to VA reimbursement rate changes. Cash reserves were CAD 320 million as of September 30. The company may pursue a reverse stock split to maintain Nasdaq compliance.